Management Strategies for POSEIDON Group 2
Copyright © 2020 Sunkara, Ramaraju and Kamath..
Although individualization of ovarian stimulation aims at maximal efficacy and safety in assisted reproductive treatments, in its current form it is far from ideal in achieving the desired success in women with a low prognosis. This could be due a failure to identify such women who are likely to have a low prognosis with currently used prognostic characteristics. Introduction of the patient-oriented strategies encompassing individualized oocyte number (POSEIDON) concept reinforces recognizing such low prognosis groups and stratifying in accordance with important prognostic factors. The POSEIDON concept provides a practical approach to the management of these women and is a useful tool for both counseling and clinical management. In this commentary, we focus on likely management strategies for POSEIDON group 2 criteria.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Frontiers in endocrinology - 11(2020) vom: 25., Seite 105 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sunkara, Sesh Kamal [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
IVF (ICSI) |
|---|
| Anmerkungen: |
Date Completed 01.02.2021 Date Revised 01.02.2021 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fendo.2020.00105 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307628388 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307628388 | ||
| 003 | DE-627 | ||
| 005 | 20231225125958.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fendo.2020.00105 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1025.xml |
| 035 | |a (DE-627)NLM307628388 | ||
| 035 | |a (NLM)32174892 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sunkara, Sesh Kamal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management Strategies for POSEIDON Group 2 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2021 | ||
| 500 | |a Date Revised 01.02.2021 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Sunkara, Ramaraju and Kamath. | ||
| 520 | |a Although individualization of ovarian stimulation aims at maximal efficacy and safety in assisted reproductive treatments, in its current form it is far from ideal in achieving the desired success in women with a low prognosis. This could be due a failure to identify such women who are likely to have a low prognosis with currently used prognostic characteristics. Introduction of the patient-oriented strategies encompassing individualized oocyte number (POSEIDON) concept reinforces recognizing such low prognosis groups and stratifying in accordance with important prognostic factors. The POSEIDON concept provides a practical approach to the management of these women and is a useful tool for both counseling and clinical management. In this commentary, we focus on likely management strategies for POSEIDON group 2 criteria | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a IVF (ICSI) | |
| 650 | 4 | |a POSEIDON classification | |
| 650 | 4 | |a POSEIDON group 2 | |
| 650 | 4 | |a poor responder | |
| 650 | 4 | |a suboptimal responder | |
| 700 | 1 | |a Ramaraju, G A |e verfasserin |4 aut | |
| 700 | 1 | |a Kamath, Mohan Shashikant |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in endocrinology |d 2010 |g 11(2020) vom: 25., Seite 105 |w (DE-627)NLM208813357 |x 1664-2392 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g day:25 |g pages:105 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fendo.2020.00105 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |b 25 |h 105 | ||